Recent Quotes (30 days)

You have no recent quotes
chg | %

Merus Labs International Inc (USA)  

(Public, NASDAQ:MSLI)   Watch this stock  
Find more results for MSLI
+0.025 (2.81%)
Mar 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.87 - 0.92
52 week 0.70 - 1.76
Open 0.88
Vol / Avg. 12,373.00/28,974.00
Mkt cap 105.53M
P/E     -
Div/yield     -
EPS -0.10
Shares 117.35M
Beta 1.81
Inst. own 0%
Feb 9, 2017
Q1 2017 Merus Labs International Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -24.23% -10.39%
Operating margin -14.24% 0.38%
EBITD margin - 44.57%
Return on average assets -6.88% -2.96%
Return on average equity -13.14% -5.00%
Employees 13 -
CDP Score - -


100 Wellington St. West Suite 2110 Stn Toronto Dom PO Box 151
+1-416-5933701 (Phone)
+1-416-5934434 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Merus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company's products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates. Sintrom is an anticoagulant indicated to treat and prevent thromboembolic diseases. Emselex/Enablex is used in adults to treat overactive bladder syndrome. Surgestone is used to treat women with menstrual irregularities due to ovulation disorder, dysmenorrhea and premenstrual syndrome. Provames is used as hormone replacement therapy in postmenopausal women with symptoms of estrogen deficiency.

Officers and directors

Michael S. Cloutier Independent Chairman of the Board
Bio & Compensation  - Reuters
Barry Fishman Chief Executive Officer, Director
Bio & Compensation  - Reuters
Michael Bumby Chief Financial Officer
Age: 51
Bio & Compensation  - Reuters
Robert McLay Vice President - Sales and Marketing
Bio & Compensation  - Reuters
Frank Rotmann Vice President and Head of European Operations
Bio & Compensation  - Reuters
Robert Bloch M.D. Director
Bio & Compensation  - Reuters
Theresa Sheila Firestone Independent Director
Bio & Compensation  - Reuters
David D. Guebert CPA Independent Director
Bio & Compensation  - Reuters
Robert S. Pollock Independent Director
Bio & Compensation  - Reuters
Timothy G. Sorensen Independent Director
Bio & Compensation  - Reuters